June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Assessment of the Long-Term Outcome of Selective Laser Trabeculoplasty (SLT) in Treatment of Different Glaucoma Types in Patients Receiving Maximum Medicinal Treatment
Author Affiliations & Notes
  • Eman Elhawy
    Ophthalmology, Wills Eye Institute, Philadelphia, PA
  • Camila Zangalli
    Ophthalmology, Wills Eye Institute, Philadelphia, PA
  • Daniel Shapiro
    Ophthalmology, Wills Eye Institute, Philadelphia, PA
  • Lalita Gupta
    Ophthalmology, Wills Eye Institute, Philadelphia, PA
  • Michael Hsieh
    Ophthalmology, Wills Eye Institute, Philadelphia, PA
  • Abigail Kasprenski
    Ophthalmology, Wills Eye Institute, Philadelphia, PA
  • L Jay Katz
    Ophthalmology, Wills Eye Institute, Philadelphia, PA
  • George Spaeth
    Ophthalmology, Wills Eye Institute, Philadelphia, PA
  • Footnotes
    Commercial Relationships Eman Elhawy, None; Camila Zangalli, None; Daniel Shapiro, None; Lalita Gupta, None; Michael Hsieh, None; Abigail Kasprenski, None; L Jay Katz, Bausch & Lomb (C), Allergan (R), Allergan (C), Allergan (F), Lumenis (R), Lumenis (F); George Spaeth, Merck (F), U.S. Patent No. 8,042,946 (P), Pfizer (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1866. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Eman Elhawy, Camila Zangalli, Daniel Shapiro, Lalita Gupta, Michael Hsieh, Abigail Kasprenski, L Jay Katz, George Spaeth; Assessment of the Long-Term Outcome of Selective Laser Trabeculoplasty (SLT) in Treatment of Different Glaucoma Types in Patients Receiving Maximum Medicinal Treatment. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1866.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate efficacy of Selective Laser Trabeculoplasty (SLT) when used as a secondary treatment for glaucoma patients receiving maximum tolerated medicinal therapy

Methods: 88 Glaucoma patients (75 POAG, 6 secondary glaucoma and 7 Normal-Pressure glaucoma) that received three or four medicinal treatments were followed up after treatment with SLT in one, three and five years intervals. Mean IOP was calculated before receiving laser treatments then compared to the IOP measured at 1, 3 and 5 years intervals. A change was defined as a better pressure when more than millimeter drop of IOP was recorded, and as worse when more than one millimeter increase of IOP was recorded. A pressure was referred to as equal when it was the same or changed by one millimeter mercury.

Results: The mean of the baseline IOP for the 88 eyes was 18.35 with a standard deviation of 5.3; the mean IOP 1 year post laser treatment was 16.47 with a standard deviation of 4.87; the mean IOP 3 years post laser treatment was 15.86 with a standard deviation of 6.43; while the mean IOP 5 years post laser treatment was 16.21 with a standard deviation of 6.16. After 1 year of receiving SLT, 57% (among 83 eyes of patients who reported for follow up) showed a drop in IOP, 17% of patients maintained the same IOP recorded before laser treatment while 27% had higher IOP . After 3 years of receiving SLT, 48% (among 50 eyes of patients who reported for follow up) showed a drop in IOP, 26% of patients maintained the same IOP recorded before laser treatment while 26% had higher IOP . At the 5 years follow up visit, 50% (among 14 eyes of patients who reported for follow up) showed a drop in IOP, 29% of patients maintained the same IOP recorded before laser treatment while 21% had higher IOP . During the follow up 2 eyes required surgery within the first year, an additional five eyes required surgical treatment within the three years following laser, as did an additional five eyes during the five years follow up.

Conclusions: In patients receiving maximal medicinal treatment, SLT showed efficacy in reducing or maintaining IOP for three years.

Keywords: 578 laser • 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×